Small Vessel Disease
Conditions
Keywords
MRI
Brief summary
Small vessel disease (SVD) accounts for 25% of strokes and is the second most common cause of dementia after Alzheimer's disease. Unlike other causes of stroke, SVD manifests itself years before the stroke by the accumulation of tissue damage. Although heterogeneous, these lesions appear on Magnetic Resonance Imaging (MRI) as white matter hypersignals (WMH). In this context, the ANR SUMMIT project will characterize these lesions in vivo to develop new markers in the early stages of stroke. It is subdivided into 4 work packages, the third one being promoted by CHRU de Tours.
Interventions
DEVICEMRI
In vivo MRI
Sponsors
University Hospital, Tours
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
82 Years to 100 Years
Healthy volunteers
Yes
Inclusion criteria
Prior Enrollement in Tours body donation program Age ≥ 82 years Able to remain supine in the MR scanner for acquisition (duration 60-minutes) Affiliation to social security Informed and written consent
Exclusion criteria
Contraindications to body donation, especially infectious disease (VIH, HBV…) Contraindications to MRI
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| In vivo and ex vivo MRI measures data | baseline | We will compare In vivo data: 20 MR datasets, 20 quantitative SUMMIT maps (predicted microstructure) Ex vivo data : * 3 very high-resolution MR datasets and derived quantitative microstructural maps * 18 brain samples: scanned at 17.2T by the Neurospin partner and processed with the SUMMIT method to obtain high-resolution quantitative microstructural maps * these 18 samples will be processed to get ground truth histological 3D volumes (Mircen partner). Maps of the microstructure parameters obtained from MRI (in and ex vivo) and the SUMMIT method will be quantitatively compared to histological data. This will validate the SUMMIT method at clinical (in vivo) and mesoscopic resolution (ex vivo). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| FLAIR and SUMMIT maps (MRI evaluation) | baseline | In vivo FLAIR and SUMMIT maps. |
| Scores at neuropsychological evaluation | baseline | Scores at neuropsychological evaluation |
Countries
France
Contacts
Primary ContactJean Philippe COTTIER, PHD
Backup ContactChristophe DESTRIEUX, PHD
Outcome results
None listed